Navigation Links
New guidelines for treating rheumatoid arthritis
Date:7/22/2008

BIRMINGHAM, Ala. Proven combinations of medicines and the introduction of new anti-arthritis drugs have significantly improved the treatment of rheumatoid arthritis (RA), according to guidelines issued by the American College of Rheumatology and co-authored by physicians at the University of Alabama at Birmingham (UAB).

Lead author Kenneth Saag, M.D., M.Sc., a professor in the UAB Division of Clinical Immunology and Rheumatology, said the new guidelines update strategies for treating RA with the goal of preventing joint damage and disability.

The new recommendations do not strive to replace individualized medical decisions, Saag said. Instead, they are meant to guide rheumatologists and other health care workers toward the most updated recommendations. The last set of American College of Rheumatology RA treatment guidelines was published in 2002.

"The recommendations developed are not intended to be used in a 'cookbook' or prescriptive manner, or to limit a physician's clinical judgment," Saag said. "They provide guidance based on clinical evidence and expert panel input."

The recommendations focus on several classes of anti-arthritic drugs, including a potent group of agents called disease-modifying anti-rheumatic drugs (DMARDs). Newer genetically engineered DMARDs called biologics often work in combination with earlier therapies. Many anti-arthritic drugs are designed to stop damaging inflammation, and biologics work to interrupt the chain of events that leads to inflammation.

Newer biologics called anti-TNF agents adalimumab (Humira), etanercept (Enbrel) and infliximab (Remicade) prevent the production of an immunity protein that plays a role in inflammation.

Some of the key recommendations include:

  • Methotrexate or leflunomide therapy is recommended for most RA patients.
  • Anti-TNF agents etanercept, infliximab, or adalimumab along with methotrexate can be used in new or early RA cases with worsening and severe symptoms.
  • Doctors should not initiate or resume treatment with methotrexate, leflunomide, or biologics if RA patients have active bacterial infection, shingles (herpes-zoster), hepatitis B, hepatitis C and active or latent tuberculosis.
  • Doctors should not prescribe anti-TNF agents to patients with a history of heart failure, lymphoma or multiple sclerosis.


'/>"/>

Contact: Troy Goodman
tdgoodman@uab.edu
205-934-8938
University of Alabama at Birmingham
Source:Eurekalert

Related biology news :

1. NHLBI issues first US von Willebrand Disease clinical practice guidelines
2. Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines
3. 2 carotid artery stenting studies show results comparable to AHA guidelines
4. UNC study questions FDA genetic-screening guidelines for cancer drug
5. Tumor-inhibiting protein could be effective in treating leukemia
6. Hebrew University develops novel approach for treating mitochondrial disorders
7. Treating chronic pain, migraine & muscle spasticity through inhibition of neurotransmitter glutamate
8. Environmental epigenetics has potential for preventing and treating disease
9. International scientists tackle obstacles to treating brain disorders
10. Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging
11. Massive microRNA scan uncovers leads to treating muscle degeneration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
(Date:12/8/2016)... 2016 Market Research Future published a half cooked research ... Biometric Security and Service Market is expected to grow over the ... Market Highlights: ... Mobile Biometric Security and Service Market ... need of authentication and security from unwanted cyber threats. The increasing ...
Breaking Biology News(10 mins):
(Date:1/16/2017)... Jan. 16, 2017   Valentin A. Pavlov, PhD ... , president and CEO of The Feinstein Institute ... analysis of how the nervous system regulates the immune ... bioelectronic medicine devices to treat disease and ... Neuroscience . The paper examines various studies ...
(Date:1/16/2017)... , Jan. 16, 2017  Eurofins Genomics today ... will allow more customers to receive their primers in ... or compromise in quality found with other providers. Express ... United States at no additional fee. ... routine genetic studies, including DNA sequencing, genotyping, site-directed mutagenesis, ...
(Date:1/14/2017)... 13, 2017  The Alliance for Safe Biologic Medicines ... FDA final guidance on biologic naming: ... in emphasizing the importance of distinct naming for all ... the benefits biosimilars will bring to patients, including new ... the portion of the Guidance dealing with suffix design ...
(Date:1/13/2017)... and Markets has announced the addition of the "Global Biopolymers Market ... ... 16.83% during the period 2017-2021. The report covers the ... 2017-2021. To calculate the market size, the report considers the revenue generated ... a a discussion of the key vendors operating in this market. ...
Breaking Biology Technology: